These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23934763)

  • 41. 21st-century oncology: a tangled web.
    Keating P; Cambrosio A
    Lancet; 2013 Dec; 382(9909):e45-6. PubMed ID: 24350356
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
    Klamová H; Poláková KM; Mužík J; Ráčil Z; Záčková D; Steinerová K; Karas M; Faber E; Demečková E; Michalovičová-Sninská Z; Voglová J; Demitrovičová L; Mikušková E; Tóthová E; Chudej J; Markuljak I; Cmunt E; Moravcová J; Dvořáková D; Michalová K; Jarošová M; Sťastná MM; Cetkovský P; Dušek L; Koza V; Trněný M; Indrák K
    Cancer Med; 2013 Apr; 2(2):216-25. PubMed ID: 23634289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mechanisms of resistance to BCR-ABL kinase inhibitors].
    Diamond J; da Silva MG
    Acta Med Port; 2013; 26(4):402-8. PubMed ID: 24016650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia.
    Radich JP
    J Natl Compr Canc Netw; 2013 May; 11(5 Suppl):663-6. PubMed ID: 23704238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.
    Park MJ; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Jeong JW; Ahn JY; Park J
    Ann Lab Med; 2014 May; 34(3):247-51. PubMed ID: 24790915
    [No Abstract]   [Full Text] [Related]  

  • 48. Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.
    Xiao Y; Hu HH; Wang HX; Zhu XJ; Zou P; Chen ZC; Zhong ZD; Li WM; You Y
    Acta Pharmacol Sin; 2012 Jul; 33(7):979-80. PubMed ID: 22684027
    [No Abstract]   [Full Text] [Related]  

  • 49. [Treatment of chronic myelogenous leukemia by using imatinib].
    Jinnai I
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
    [No Abstract]   [Full Text] [Related]  

  • 50. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
    Moser O; Krumbholz M; Thiede C; Tauer JT; Janz I; Lauten M; Dilloo D; Metzler M; Suttorp M
    Pediatr Blood Cancer; 2014 Nov; 61(11):2080-2. PubMed ID: 24810322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCR-ABL kinase is dead; long live the CML stem cell.
    Perl A; Carroll M
    J Clin Invest; 2011 Jan; 121(1):22-5. PubMed ID: 21157035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate.
    Takahashi N; Kameoka Y; Tagawa H; Saitoh H; Yoshioka T; Fujishima N; Kitabayashi A; Takahashi K; Hirokawa M; Sawada K
    Int J Hematol; 2010 Oct; 92(3):559-61. PubMed ID: 20838959
    [No Abstract]   [Full Text] [Related]  

  • 57. [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
    Sawadogo S; Hien FM; Ouédraogo MS; Drabo YJ
    Pan Afr Med J; 2014; 18():142. PubMed ID: 25419280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Towards a cure for chronic myeloid leukemia: are we there yet?
    Cortes J
    Semin Hematol; 2010 Oct; 47(4):299-301. PubMed ID: 20875545
    [No Abstract]   [Full Text] [Related]  

  • 60. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.